Pfizer’s “Blue Sky” approach to transforming clinical research in Parkinson’s disease is an inspiring example of patient-centric innovation. Conference Forum's, Valerie Bowling welcomes co-host, Ed Miseta, Clinical Leader.com in a discussion with members of Pfizer’s "Blue Sky" team. Together they discuss the vision, goals and journey in taking a new approach to advancing drug development. More specifically, the Blue Sky team talks about their partnership with IBM, (first of its kind) decisions on how to use a device in a trial, real time data collection, an 1800s house for a 21st Century research and more.

Co-Hosts:

Valerie Bowling, Executive Director, The Conference Forum

Ed Miseta, Chief Editor, Clinical Leader and Contributing Writer, Life Science Leader

Guests:

Stephen Amato, PhD, Project Manager, BlueSky, Pfizer

David Caouette, MBA, Senior Director, Strategy and Operations Lead, BlueSky and Quantitative Medicine, Pfizer

Daniel Karlin, MD, Senior Director, Quantitative Medicine, Clinical Lead, BlueSky, Pfizer

Both Drs David Caouette and Daniel Karlin are co-presenting at the DPharm conference on September 20th in Boston. For more information go to www.theconferenceforum.org.

Pfizer's Blue Sky Approach to Help Transform Clinical Research

Share

Embed